We just ended Unitaid's Executive Board in South Africa, and the headline outcomes are (i) lenacapavir and (ii) climate-smart health products. 👉 The Board recognized the importance of long-acting lenacapavir. Some innovations, when made widely and equitably accessible, can change the life of millions of people and the face of a disease. Long-acting lenacapavir is potentially one such innovation. Our site visits near Johannesburg also confirmed this potential: many clients seem to express preference for injectable PrEP over oral PrEP. This is why Unitaid has already launched investments to accelerate access to this critical new innovation. 👉 This Board session also marked the approval of Unitaid's first Climate and Health Area for Intervention. Under this new area of work, Unitaid aims to help communities adapt to climate-related health threats, reduce the environmental footprint of key health products and ensure their resilience to climate-related shocks, and drive sustainable innovation in global health systems. Lots of exciting work and amazing learning ahead of us. And these two main Board outcomes are actually more related than they look. Long-acting injectable treatments like lenacapavir hold the promise of being triple wins for public health and climate: better health outcomes (due to better adherence/convenience), more climate-resilient health interventions (reduced risk of treatment interruption in case of climate shocks and health system disruption) and lower carbon footprint (due to smaller API content relative to oral equivalents). It is hard to think of a better example of a climate-smart product! Duneton Philippe Tenu Avafia Janet Ginnard Carmen Pérez Casas Anne-Isabelle Cameron Matthew Lindley Julien Pouille Stéphanie Mariat Maria Neira Patrick Gitonga Diarmid Campbell-Lendrum
At its 45th session, Unitaid’s Executive Board prioritized bold action on global health by accelerating lenacapavir’s roll-out and committing to climate-smart health products to create sustainable and resilient health systems. Find out more: https://lnkd.in/emdCjfgi